|
|
 |
|
By Principal Investigator:
U V W X Y Z
| Principal Investigator |
Title |
IRB#: |
| Vichinsky, Elliott MD |
MSH (Multicenter Study of Hydroxyurea) Patients' Follow Up Study |
1997-005 |
| Vichinsky, Elliott MD |
Secondary Hemochromatosis in B-Thalassemia and Sickle Cell Disease |
1999-026 |
| Vichinsky, Elliott MD |
Cellular Mechanisms for Iron Storage in B Thalassemia and Sickle Cell Disease and Correlation with Oxidative Injury |
2000-026 |
| Vichinsky, Elliott MD |
Thalasemmia Clinical Research Network Registry |
2001-023 |
| Vichinsky, Elliott MD |
Thalassemia Clinical Research Network Hepatitis C Clinical Trial |
2003-010 |
| Vichinsky, Elliott MD |
A Pilot Study of the Response of Oxidant Stress Induced Injury and Mitochondrial Dysfunction Biomarkers to Treatment with Iron Chelators: Ancillary Study of the Novartis ICL670 107 Open Label Phase III Trial |
2003-011 |
| Vichinsky, Elliott MD |
A 3-Year Extension to a Multi-Center, Open-Label, Non-Comparative, Phase II Trial on Efficacy and Safety of ICL670 (5 to 40 mg/kg/day) Given for at Least 1 Year to Patients with Chronic Anemias and Transfusional Hemosiderosis (ICL670 108E) |
2004-063 |
| Vichinsky, Elliott MD |
Neuropsychological Dysfunction and Neuroimaging Abnormalities in Neurologically Intact Adults with Sickle Cell Disease |
2004-081 |
| Vichinsky, Elliott MD |
A Protocol to Allow Treatment with ICL670 for Patients with or at Risk of Life-Threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity (ICL670A0117) |
2005-013 |
| Vichinsky, Elliott MD |
The Sickle Cell Disease Collaborative Data Project |
2005-020 |
| Vichinsky, Elliott MD |
A One Year Open-Label , Non-Comparative Extension to a Randomized, Multicenter, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and the Effects on Liver Iron Concentration of Repeated Doses of 5-30 mg/kg/day of ICL670 Relative to Def |
2005-003 |
| Vichinsky, Elliott MD |
A Randomized, Open-Label, Multi-Center, Phase II Study to Evaluate the Safety and Efficacy of Oral ICL670 (Deferasirox) 20 mg/kg/day Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients w/ Iron Overload from Repeated Blood Transfusions |
2005-037 |
| Vichinsky, Elliott MD |
Phase II Randomized, Double Blind, Placebo-Controlled Trial comparing the Effect of Deferoxamine with or without Oral Deferiprone (L1) on Cardiac Left Ventricular Function Assessed by MRI in Adults with Transfusion-Dependent Beta-Thalassemia |
2005-084 |
| Vichinsky, Elliott MD |
The Compassionate Use of Ferriprox (Deferiprone) in Patients with Transfusion Dependent Anemia and Chronic Iron Overload (Apotex Inc.) |
2005-087 |
| Vichinsky, Elliott MD |
Epidemiology of Priapism |
2005-090 |
| Vichinsky, Elliott MD |
The Collaborative Data Project |
2006-007 |
| Vichinsky, Elliott MD |
A Longitudinal Cohort Study of Patients with Thalassemia in the Thalassemia Clinical Research Network |
2006-073 |
| Vichinsky, Elliott MD |
Effectiveness of Hydroxyurea and Magnesium Pidolate Alone and in Combination in Hemoglobin SC Disease: A Phase II Trial |
2007-001 |
| Vichinsky, Elliott MD |
A 5 Year Observational Study (registry) of Children Aged 2 to <6 Years at Enrollemnt with Hemosiderosis Treated with Deferasirox |
2007-017 |
| Vichinsky, Elliott MD |
Safety of Deferasirox (ICL670) and Deferocamine (Desferal or DFO) Combined Chelation Therapy in Patients with Transfusion Dependent Thalassemia and Ironoverload |
2007-040 |
| Vichinsky, Elliott MD |
Open label, dose escalation, Phase I / pilot study is designed to provide preliminary evidence of the safety, pharmacokinetics (PK), and pharmacodynamic (PD) activity of pentosan polysulfate sodium (PPS) given orally as a single dose to subjects with sickle cell disease |
2007-071 |
| Viteri, Fernando MD, PhD |
Determination of Folate Levels in Density Fractionated Human Erythrocytes & In Vitro Kinetics of Folate Uptake / Efflux by Purified Red Blood Cells |
2007-035 |
| Viteri, Fernando MD, PhD |
Globalization, Bi-national Communities and Imported Food Risks: An Outbreak Investigation of Lead Poisoning in Monterey, California. |
2008-034 |
| Viteri, Fernando MD, PhD |
Effectiveness of NaFeEDTA and FeSO4 on Inhibiting Lead Absorption |
2008-035 |
| Wachtel, Renee MD |
Rett Syndrome Natural History |
2005-085 |
| Wachtel, Renee MD |
An Open-Label Study to Evaluate the Safety of Donepezil Hydrochloride (Aricept®) for up to 1 Year in the Treatment of the Cognitive Dysfunction Exhibited by Children with Down Syndrome - Follow-Up to a 10 Week, Double-Blind, Placebo-Controlled Trial (A2501060) |
2008-040 |
| Walters, Mark MD |
Allogeneic Marrow Transplantation from HLA-Identical Related Donors for Treatment of Homozygous Thalassemia Major and other Red Cell Disease (Excluding Sickle Cell Anemia) Activation Date 6/23/93 |
2000-005 |
| Walters, Mark MD |
Pilot Study of High Dose Chemotherapy with Busulfan, Melphalan and Topotecan with Peripheral Blood Stem Cell Rescue in Advanced Stage and Recurrent Tumors |
2002-050 |
| Walters, Mark MD |
International Bone Marrow Registry/Autologous Blood & Marrow Transplant Registry (IBMTR/ABMTR) |
2002-077 |
| Walters, Mark MD |
Cyclophosphamide and Antithymocyte Globulin Conditioning Regimen for Marrow Transplantation from HLA-Matched Family Members for Severe Aplastic Anemia: Effect of Marrow Cell Dose on Chronic Graft-vs.-Host Disease: A Multi-Center Study (2054.00-FH) |
2006-046 |
| Walters, Mark MD |
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute, Non-infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation. ASCT0521 |
2006-091 |
| Walters, Mark MD |
Hematopoietic Cell Transplantation for Treatment of Patients with Primary immunodeficiencies and other Nonmalignant Inherited Disorders using low-dose TBI and Fludarabine with or Without Campath®. (2007-FH) |
2007-011 |
| Walters, Mark MD |
A Randomized Trial of Sirolimus-Based Graft versus Host Disease Prophylaxis after Hematopoietic Stem Cell Transplantation in Relapsed ALL. COG ASCT0431 (PBMTC ONC051) |
2007-013 |
| Walters, Mark MD |
Multi-Center, Open Label, Randomized Trial Comparing Single versus Double Umbilical Cord Blood Transplantation in Pediatric patients with High Risk Leukemia or Myelodysplasia. (BMT-CTN-0501) |
2007-072 |
| Walters, Mark MD |
Compassionate Use Protocol for the use of AMD3100 to Mobilize Peripheral Blood Stem cells for Collection and Transplantation. |
2008-004 |
| Walters, Mark MD |
Unrelated Donor Hematopoietic Cell Transplantation for Children with Severe Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen-(BMTCTN 0601) |
2008-038 |
| Waterson, John MD PhD |
MPS I Registry Protocol and Patient Information and Authorization for Release of Clinical Information to the MPS I Registry |
2004-096 |
| Zlotnick, Cheryl RN DrPH |
Needs and Implications for Group Work to Promote Resiliency for Inner City Minority Girls |
2004-101 |
| Zlotnick, Cheryl RN DrPH |
The Social Environment of Oakland Teens |
2004-077 |
| Zlotnick, Cheryl RN DrPH |
Health Status and Behaviors of Adults with Histories of Foster Care |
2005-040 |
| Zlotnick, Cheryl RN DrPH |
Substance Abuse, Child Neglect and Homeless Families |
2005-006 |
| Zlotnick, Cheryl RN DrPH |
Health Care provided to the Homeless (HCH) |
2005-095 |
| Zlotnick, Cheryl RN DrPH |
Focus Groups on Successful Parenting |
2006-041 |
| Zuluaga, Maria T. MD |
Use of Brain Near Infrared Spectroscopy (NIRS) in Children with Intracranial Hypertension |
2006-098 |
Revised:
Monday, July 7, 2008 10:39 AM
|
Cholesterol Research Center 
Thalassemia Clinical Research Network
